Biessels GJ, Verhagen C, Janssen J, et al. - In people with type 2 diabetes with cardiorenal disease, experts explored if the dipeptidyl peptidase 4 inhibitor linagliptin could prevent cognitive decline. In addition to standard of care, the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA)-COG substudy was an integral part of CARMELINA that randomized candidates with cardiorenal disease to linagliptin 5 mg or placebo once daily (1:1). Of the 6,979 candidates in CARMELINA, CARMELINA-COG included 1,545 (mean ± SD age, 68 ± 8 years). Investigators found that linagliptin did have an impact on cognitive decline over 2.5 years in a large, international cardiovascular outcome trial in people with type 2 diabetes and cardiorenal disease.